14 Sep
2021

New Humira decision changes venue selection playbook for US biosimilar patent disputes

As forum shopping takes on greater strategic importance in BPCIA disputes, a Northern District of Illinois decision suggests patentees will have more latitude when selecting venues for litigation against biosimilar producers with foreign parent companies

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth